JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/01.qai.0000446751.50448.49
Abstract Index

Abstract Index

Free Access
Collapse Box

Author Information

* GVN Member

101 Biomedical Prevention of HIV/AIDS in Russia

E. V. Karamov, R. M. Khaitov

National Research Centre Institute of Immunology, FMBA of Russia

102 HIV/AIDS Vaccines in Russia: Clinical Trials and Estimation of Acceptance in Population

G. O. Gudima

National Research Centre Institute of Immunology, FMBA of Russia

103 Genetic Factors Defining Resistance and Susceptibility to HIV/AIDS

I. A. Kofiadi

National Research Centre Institute of Immunology, FMBA of Russia

104 Cell-to-cell Transmission of HIV-1: Role of Virological Synapse

A. V. Filatov, D. V. Mazurov

National Research Centre Institute of Immunology, FMBA of Russia

105 Rationale for HIV/AIDS Vaccines Design

I. A. Nikolaeva

National Research Centre Institute of Immunology, FMBA of Russia

106 Enhance Expression of Transgene in Adenovirus

R. I. Ataullakhanov

National Research Centre Institute of Immunology, FMBA of Russia

107 The Modern Methods of HIV/AIDS Vaccine Evaluation

S. V. Korobova

National Research Centre Institute of Immunology, FMBA of Russia

108 Development of Universal Vaccines against Flu

M. M. Shmarov

Gamaleya Scientific Research Institute of Epidemiology and Microbiology of the Health Ministry of the Russian Federation (Russia)

109 Genetically Engineered Tuberculosis Subunit Vaccine

A. V. Tkachuk

Gamaleya Scientific Research Institute of Epidemiology and Microbiology of the Health Ministry of the Russian Federation (Russia)

110 Broadly Neutralizing Antibodies for Serotherapy and Vaccine Design

Antonio Lanzavecchia, MD

Director of the Institute for Research in Biomedicine (Switzerland)

111 Update on Dengue Vaccines

Alexander Schmidt, MD

Director, Clinical Research and Translational Science, GlaxoSmithKline Biologicals (US)

112 Development of Enterovirus 71 Vaccine

Li Xiuling

National Vaccine and Serum Institute (China)

113 Epidemics of Acute Gastroenteritis Caused by Viruses and Vaccine Development in China

Shen Shuo, PhD

Wuhan Institute of Biological Product (China)

114 Virus-Like Particles and Particle Vaccines

Luigi Buonaguro, MD

Ist. Naz.Tumori “Fond. G. Pascale” (Italy)

115 Novel HIV Vaccine Strategies

Dan Barouch, MD, PhD

Director of the Centre for Virology and Vaccine Research in the Department of Medicine at Beth Israel Deaconess Medical Center (US)

116 Strategies and Mechanisms for Induction of Mucosal T Cell Immunity

Jay A. Berzofsky, MD, PhD

Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute (US)

117 30 Years of HIV Vaccine Research

José Esparza, MD, PhD

Senior Advisor on HIV Vaccines of the Bill and Melinda Gates Foundation (US)

118 The Dense Glycan Shield on the HIV Envelope: the Achilles Heel of the Virus?

Jan Balzarini, MD, PhD

Laboratory of Virology and Chemotherapy, Rega Institute (Belgium)

119 The Anti-HIV Drug Pipeline

John G. Bartlett, MD

Director, HIV Care Program, The Johns Hopkins Hospital (US)

120 Development of New HIV Inhibitors

S.N.Kochetkov

Laboratory of Enzymology of Transcription, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences

121 Progress, Achievements and Challenges: a Review of China’s Free Antiretroviral Therapy Program

Fujie Zhang, MD

National Centre for AIDS/STD Control and Prevention (China)

122 Peptide Inhibitors of HIV

Anders Vahlne, MD

Karolinska Institute (Sweden)

123 New Antiretroviral Therapies

James Rooney, MD

Vice President of Medical Affairs, Gilead Sciences, Inc. (US)

124 HIV Transmission and Pathogenesis in ex vivo Tissues

Leonid Margolis, PhD

Head, Section of Intercellular Interactions, Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)

125 Progress toward a HIV cure

Alain Lafeuillade, MD

Department of Infectious Diseases, Toulon General Hospital (France)

126 Questions and challenges in HIV drug resistance: A molecular perspective

Luis Menéndez-Arias, PhD

Centro de Biologia Molecular “Severo Ochoa” (CSIC-UAM), Madrid (Spain)

127 Safety, pharmokinetics and efficacy of VM-1500, a novel reverse transcriptase inhibitor, In healthy volunteers and HIV-infected patients

Vadim Bichko, M.D.

Viriom Ltd. (Russia)

128 Cure of HBV infection: can APOBEC3 deaminases mediate it?

Ulrike Protzer, MD

Institute of Virology, TU Munich (Germany)

129 Polio Vaccines: The Past, Present and the Future

Konstantin Chumakov, PhD

Chief of the Laboratory of Method Development, Division of Viral Products in the Food and Drug Administration (US)

130 HTLV-I and Adult T Cell Leukemia/Lymphoma (ATLL): Cellular and Molecular Basis of Transformation

William Hall, MD

University College, Dublin (Ireland)

131 Replication and Assembly of Filoviruses

Stephan Becker, PhD

Institute of Virology at the University of Marburg (Frankfurt, Germany)

132 A Novel Pathway of Proviral HIV-1 Latency Regulated by Aminoacid Starvation and HDAC-4

Guide Poli, MD

Head, AIDS Immunopathogenesis Unit, San Raffaele Scientific Institute (Italy)

133 Ebola virus matrix: structural transformation begets multiple structures in the virus life cycle

Erica Ollmann Saphire, PhD

Department of Immunology and Microbial Science of the Scripps Research Institute (US)

134 Host Restriction of Schmallenberg Virus

Massimo Palmarini, DVM, Ph.D., FRSE

Chair of Virology, University of Glasgow Centre for Virus Research (UK)

135 HIV-associated immunodeficiency despite potent antiretroviral therapy with CD4 T cell reconstitution

C. David Pauza, PhD

Institute of Human Virology, University of Maryland School of Medicine (US)

136 HIV-1 Nef regulates activity of endoplasmic reticulum chaperone calnexin

Michael Bukrinsky, MD, PhD

Department of Microbiology, Immunology and Tropical Medicine at the George, Washington University (US)

137 Interplay Between Host Defenses and Viral Anti-defenses: A Major Factor of Cytopathogenicity of Picornaviruses

V.I.Agol, MD, PhD, DSc

M.P.Chumakov Institute of Poliomyelitis and Viral Encephalitis, Russian Academy of Medical Sciences (Russia)

138 Understanding protective immunity: Lessons from measles

Diane Griffin MD, PhD

Alfred and Jill Sommer Professor, Chair of the Department of Molecular Microbiology and Immunology, the Johns Hopkins Bloomberg School of Public Health (US)

139 Dengue Vector Control: Critical Needs and Opportunities for Helping to Control the Dengue Pandemic

Barry J. Beaty, PhD

University Distinguished Professor, Department of Microbiology, Immunology and Pathology, Colorado State University (US)

140 Reversing the Epidemic of HIV-1C in Southern Africa with Treatment as Prevention

Myron Essex, DVM, PhD

Mary Woodard Lasker Professor of Health Sciences Harvard School of Public Health, Harvard University (US)

141 Gene Discovery and Data Sharing in Genome Wide Association Analyses: lessons from AIDS genetic restriction genes

Steven O’Brien

St. Petersburg State University (Russia)

142 Sochi Virus as a Highly Pathogenic and Life-threatening Agent

E.A.Tkachenko, MD, PhD, DSc

M.P. Chumakov Institute of Poliomyelitis and Viral Encephalitis, Russian Academy of Medical Sciences (Russia)

143 Rift Valley Fever Virus: a Virus with Potential for Global Emergence

Janusz T. Paweska, DVSc, dr hab., Prof Vet. Sci.

Head, Centre for Emerging and Zoonotic Diseases, National Institute for Communicable Diseases National Health Laboratory Service (South African Republic)

144 Viral-Bacterial Mixed Infections Transmitted by Ticks: Diagnosis and Prevention in Russia

E. I. Korenberg

Gamaleya Scientific Research Institute of Epidemiology and Microbiology of the Health Ministry of the Russian Federation

145 Arbovirus and Related Infectious Diseases in China

Guodong Liang, MD

National Institute for Viral disease Control and Prevention, China CDC (China)

146 Understanding the Pathogenesis of Prion and Surveillance for Human Prion Diseases in China

Xiaoping Dong, PhD

National Institute for Viral Disease Control and Prevention, China CDC (China)

147 Globalization and New Challenges Caused of Communicable Diseases

Saulius Chaplinskas, MD, PhD

Director, Center for Communicable Diseases and AIDS (Vilnus, Lithuania)

148 HPV, HIV, and Cancer: A Global Challenge

Silvia Franceschi, MD

Special Advisor, Head, Infections and Cancer Epidemiology Group, International Agency for Research on Cancer (IARC) (Lyon, France)

149 HCV and Lymphoma

Anna Linda Zignego, MD, PhD

Director, Interdepartmental Center MaSVE, Department of Experimental and Clinical Medicine, University of Florence (Italy)

150 Carcinogenesis of HPV

Franco M. Buonaguro, MD

Director, Molecular Biology and Viral Oncogenesis Unit, National Cancer Institute “Fondazione G. Pascale” (Naples. Italy)

151 Tumorigenic Polyoma Viruses

Patrick Moore, MD, MPH

Professor, Department of Microbiology and Molecular Genetics, School of Medicine and Department of Infectious Diseases and Microbiology, University of Pittsburgh (US)

152 Insights into the pathogenesis of HHV8-driven body cavity lymphomas

Luigi Chieco-Bianchi, MD

Immunology and Molecular Oncology, Veneto Institute of Oncology, Dept of Surgery, Oncology & Gastroenterology, University of Padua (Italy)

153 Molecular Pathogenesis by HTLV-1 bZIP Factor

Masao Matsuoka, MD, PhD

Institute for Virus Research, Kyoto University (Japan)

154 HIV and Cancer in Africa

William A. Blattner, MD

Professor and Associate Director, Institute of Human Virology, University of Maryland School of Medicine (US)

155 Evolution by Tumor Neofunctionalization and Phenomenon of Tumor Specifically Expressed, Evolutionarily Novel (TSEEN) Genes

A. P. Kozlov

Professor and Director, Biomedical Center (St. Petersburg, Russia)

156 HIV and metabolic disease: Clues to control of HIV infection from the immune and viro logical response to high dose Vitamin D challenge

Barry Peters, MBBS, DFFP, MD, FRCP

King’s College London (UK)

157 Pathogenesis of Epstein-Barr Virus-driven Lymphomas of HIV+ Patients: new insights of potential clinical relevance

Riccardo Dolcetti, MD

Head, Cancer Bio-Immunotherapy Unit, IRCCS—National Cancer Institute (Italy)

158 Hepatitis C Treatment Update: Current Status and Future Directions

Shyam Kottilil, MD, PhD

National Institute of Allergy and Infectious Diseases (US)

159 Hepatitis B Treatment Update: Current Status and Future Directions

Rohit Talwani, MD

Institute of Human Virology, University of Maryland School of Medicine (US)

160 Treatment Strategies to Minimize the Impact of Antiretroviral Drug Toxicities

Bruce Gilliam, MD

Institute of Human Virology, University of Maryland School of Medicine (US)

161 Anti-tuberculosis Treatment for HIV-positive Patients in Moscow

E.M.Bogorodskaya, MD, PhD

Moscow City Research and Practical Centre for Tuberculosis Control (Russia)

162 Confronting Tuberculosis in an African Population with HIV

Abubakar Mussa Maghimbi, MD, MMed

Institute of Human Virology (Dar es Salaam, Tanzania)

163 HIV and kidney function with a focus on traditional risk factors and role of TDF, PI and other medication

Patrick Mallon, MD, PhD

Associate Dean for Research and Innovation, UCD School of Medicine and Medical Science (Ireland)

*Abstracts appear as provided by authors

© 2014 by Lippincott Williams & Wilkins

Login